Bacteriophage products have been first-ever included into the European Position Paper on Rhinosinusitis and Nasal Polyps (EPOS) as an alternative treatment of chronic rhinosinusitis.
The revised version of the document dated 2020 considers the products as the alternative of antibiotics in the fight with Staphylococcus aureus and other bacteria, including with multiple drug resistance, inducing infections in the nose and paranasal sinuses. Besides, the document highlights a potential efficiency of bacteriophages against biofilms.
Rhinosinusitis is an inflammation of the mucous membranes of accessory sinuses of the nose which often is developed as a complication after ARVI, in acute runny nose and other infectious diseases. Sinusitis can be caused by both viruses and bacteria.
In bacterial rhinosinusitis, antimicrobial drugs are prescribed in more than 80% cases preventively, which fact makes the disease the fifth frequent reason for antibiotics use.
In Russia, the only manufacturer of Bacteriophage products for the most common bacterial infections treatment, including mucosal diseases, is NPO Microgen.
EPOS-2020 is a European consensus paper for rhinosinusitis and nasal polyposis, most fully analyzing all aspects of diagnostics and treatment of diseases from the standpoint of modern evidence based medicine. The Position Paper had three revisions - in 2007, 2012, and 2020. The last version was published in the February issue of Rhinology (official journal of the European and International Rhinologic Societies).
The list of authors participated in the development of EPOS-2020 includes two Russian leading experts in otorhinolaryngology: A.S. Lopatin, Professor, Candidate of Medical Science, President of Russian Rhinologic Society, and S.A. Karpishchenko, Professor, Candidate of Medical Science. Today, this is one of the most reputable and cited sources, whose recommendations regulate the treatment of rhinosinusitis by ORT specialists from Europe and Russia.
SPA Microgen JSC is a unique enterprise for biopharmaceuticals production in the RF, which supplies over a half of the total scope of vaccines of the National Preventive Immunization Schedule (NPIS). The brand portfolio of the Company includes over 250 drugs.
